Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 1611

Treatment of Airway Hyperreactivity

Inventors: Dale Umetsu, Muriel Pichavant, Rosemarie DeKruyff, Everett Meyer, Stephanie Shore

Invention Types: Therapeutics

Research Areas: Allergy/Respiratory/Pulmonary Disease, Inflammation

Keywords: Disease Model, Patient Care

For More Information Contact:  Meyer, Abbie

 

Invention Description:

Airway hyper reactivity, a cardinal feature of asthma, results in the sudden narrowing of air passages of the lungs in response either to allergen or non-allergen stimuli. The investigators have discovered a key role of interleukin 17 (IL-17) in non-allergic asthma, and have demonstrated protection against airway hyperactivity in a model with antagonism of IL-17 signaling. By neutralizing the proinflamatory and chemotactic effects of IL-17 using an IL-17 antagonist, the development of ozone-induced airway hyper reactivity can be prevented. Ozone-induced airway hyper reactivity, in contrast to allergen-induced airway hyper reactivity, does not involve adaptive immunity or eosinophils, but rather requires natural killer T (NKT) cells and neutrophils. While IL-17 may exacerbate allergen-induced AHR, it appears to be essential in ozone-induced airway hyper reactivity.

Applications:

Cell Therapy

Competitive Advantages:

More effective and specific treatment of non-allergen induced asthma.

Business Opportunity:

Exclusive License

Key Publications: Pichavant M, Goya S, Meyer EH, et al. Ozone exposure in a mouse model induces airway hyperreactivity that requires the presence of natural killer T cells and IL-17. J Exp Med. 2008 Feb 18;205(2):385-93.

IPStatus: Pat. Pend.